🟢 Hepatitis C Antiviral Treatment (DAA)
This tool gives the HCV direct-acting-antiviral regimen direction by cirrhosis status and pregnancy, with pre-treatment assessment and the SVR12 endpoint.
Hepatitis C Antiviral Treatment (DAA)
Cirrhosis status
Pregnancy
When to use
Use to choose a pangenotypic regimen in non-cirrhotic/compensated disease, a specialist SOF/VEL + RBV regimen in decompensation, and to defer therapy in pregnancy.
How it works
No cirrhosis/compensated → SOF/VEL 12 weeks or GLE/PIB 8 weeks. Decompensated → protease inhibitors contraindicated, SOF/VEL + RBV 12 weeks. Pregnant → defer. Endpoint SVR12.
Key points
- Protease-inhibitor regimens are contraindicated in decompensated cirrhosis, which is managed by hepatology with SOF/VEL + ribavirin. (original synthesis · not guideline verbatim)
- Pre-treatment HBsAg screening prevents HBV reactivation during DAA therapy.
- Cirrhotic patients continue HCC surveillance even after achieving SVR.
References
- AASLD-IDSA. Recommendations for Testing, Managing, and Treating Hepatitis C.
- Chinese Society of Hepatology. Guideline for the prevention and treatment of hepatitis C (2022 version).
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.